




UNIVERSITI MALAYA

*Syarahan Perdana*

# **SNAKE VENOM** **The Amazing Poison**

LG173  
A9Tan

Profesor Tan Nget Hong





UNIVERSITI MALAYA

SYARAHAN PERDANA

“ **SNAKE VENOM**  
*The Amazing Poison* ”

13 Januari 2005

Perpustakaan Universiti Malaya



A510795643

Profesor Tan Nget Hong

Jabatan Perubatan Molekul  
Fakulti Perubatan, Universiti Malaya  
Kuala Lumpur, Malaysia

047745





**Profesor Tan Nget Hong**  
*Department of Molecular Medicine  
Faculty of Medicine, University of Malaya  
Kuala Lumpur, Malaysia*

## Professor Dr. Tan Nget Hong

BSc, MSc, PhD (Chicago)

**Profile:** Prof Dr Tan Nget Hong is well known for his research on Malaysian snake venoms. He had served as the President of the International Society on Toxinology, Asia Pacific Section. He has supervised many PhD and MSc students in the field of Biomedical Studies of snake venom. He is also active in medical education research and medical curriculum design. He has carried out collaborative research with researchers from Italy and China.

**Department/Faculty:** Department of Molecular Medicine  
Faculty of Medicine, University of Malaya

**Administrative Position:** Chairman, Knowledge Subcommittee, Curriculum Implementation Committee, Faculty of Medicine

**Education:**

1976	PhD (Bioorganic Chemistry) University of Chicago, Chicago, USA
1974	MSc (Bioorganic Chemistry) University of Chicago, Chicago, USA
1972	BSc (Chemistry) National University Taiwan, ROC

### Career:

- Professor, University of Malaya, Kuala Lumpur (1994-present)
- Assoc Professor, University of Malaya, Kuala Lumpur (1985-1994)
- Lecturer, University of Malaya, Kuala Lumpur (1977-1984)

### Professional memberships:

- (1) Malaysia Institute of Chemistry (IKM)
- (2) Malaysia Society on Toxinology
- (3) Malaysian Biochemical Society
- (4) International Society on Toxinology

## Professional activities

- (1) President, Asia-Pacific Section, International Society on Toxinology 1993-1996
- (2) Secretary General, Asia-Pacific Section, International Society on Toxinology (1990-1993)
- (3) Council Member, International Society on Toxinology 1993-1996
- (4) Auditor, Asia Pacific Society on Problem-Based Learning
- (5) Panel Member, LAN
- (6) Editorial Board, Biochemical Preparation
- (7) Council Member, Malaysian Institute of Chemistry (1982, 1987)
- (8) Council Member, Malaysian Scientific Association (1990-1991)

## Honours and Awards:

- Excellent Service Award, University of Malaya (1993, 1995, 2001)
- 12<sup>th</sup> International Union of Biochemistry Congress Travel Fellow (1982)
- Asean Regional Fellowship (1981)

**Address** : Department of Molecular Medicine  
Faculty of Medicine  
University of Malaya  
50603 Kuala Lumpur  
Malaysia

**Telephone No.** : 03-79674912

**Fax No.** : 03-79674957

**E-mail Address** : tanngethong@yahoo.com.sg

**Web site** : www.tanngethong.com

## Research Interests:

- Biomedical Studies on Venom Toxins
- Medical Education and Problem-Based Learning

## 大馬毒蛇品種達40種 毒液可供醫療研究

「科學家利用毒液中的突觸神經毒素了解神經肌肉自動集縮原理如重症肌無力。毒液中的成分也能用來松弛肌肉。」

### ?? 你知道嗎?

《A打尼毒也(4日訊) 我國的毒蛇超過40種, 可提供科學家研究其毒液的醫療價值, 包括研製新的醫療用途。

「科學家利用毒液中的突觸神經毒素了解神經肌肉自動集縮原理如重症肌無力。毒液中的成分也能用來松弛肌肉。」

#### 大馬毒蛇屬3大類

馬來西亞共有蛇類逾500種, 目前已有40種毒蛇。我國毒蛇主要屬3大類, 即响尾蛇科、蝮蛇科和蝮蛇科。

這些蛇的毒液含有70%~80%蛋白質和



陳金軍講授我國的毒蛇屬種及其醫療用途。

豐富的金屬、氨基酸、鈣、鎂和化合物與酶等。

據表示, 過去, 科學家對毒液的生命毒性研究(如A打尼) 要了解這些毒液引起生理作用, 透過毒蛇咬傷的治療方法, 例如, 使用抗毒的治療劑和抗蛇毒的。

他舉例, 聚糖的毒液通常造成神經肌肉中毒, 這種蛇咬傷的治療法是毒液的研究對象, 科學家利用這些毒液來觀察它們對產生的反應, 進而研製藥物。

他指, 响尾蛇的毒液會造成出血, 聚糖咬人會因為血小板減少和去紅血球蛋白的影響而導致。

#### 研發特效的解毒

「在了解各種類後, 科學家可研製特效的解毒劑。這種的解毒劑, 能固定毒液對血液的毒, 防止其對血液, 從而防止神經系統死亡。」

另外, 他表示, 由于研製和製造成本高昂, 我國一般尚內保製成藥物。

他指出, 在英國, 毒蛇咬傷造成死亡率約是0.300%, 但如可製成下毒人的研究。

因此, 他建議, 在蛇咬傷的急救應儘量保持冷靜, 躺下, 減少活動, 每人可以準備傷口, 用干泥泥打傷口毒液, 包括傷口清潔和消毒的藥物, 避免造成感染等。咬傷人必須送醫院, 才能可製成藥物, 能處理, 方便醫生選擇中和毒性的藥物。

This article first appeared in *Sin Chew Daily*  
on Saturday, 15th Jan 2005





## SNAKE VENOM: THE AMAZING POISON

Prof. Tan Nget Hong  
Department of Molecular Medicine  
Faculty of Medicine, University of Malaya  
Kuala Lumpur, Malaysia

### Synopsis

Snakebite is a serious medical problem in Malaysia. During the period 1958 to 1980, as many as 55000 cases of snakebites were admitted to the hospitals of Malaysia. In Malaysia there are more than 40 different species of venomous snakes, belonging to three families: the crotalids (pit viper), elapids (cobras and kraits) and the sea snakes.

Dried snake venom contains mainly proteins (70-90%) and small amounts of metals, amino acids, peptides, nucleotides, carbohydrates, lipids and biogenic amines. The major toxins are proteins. Investigations of the biochemistry and toxinology of snake venoms have led to a better understanding of the pathophysiology of snake venom poisonings and improvement in the treatment of snakebites as well as the discovery of novel therapeutic agents and biomedical tools.

Elapid venoms generally exhibit neurotoxicity and cardiotoxicity. The major toxins of the elapid venoms include polypeptide postsynaptic neurotoxins, polypeptide cardiotoxins and phospholipases A. These toxins are valuable molecular probes and pharmacological tools to investigate the functional biology of receptors and ion channels as well as providing lead compounds for the design of clinically useful drugs. Postsynaptic neurotoxins, for example, play an important role in understanding of the pathogenesis of auto-immune neuromuscular diseases such as Myasthenia gravis. Candoxin, a neurotoxin from Malayan krait, is a useful tool in the investigation of molecular basis of Alzheimer's disease as well as a muscle relaxant.



The crotalid venoms generally cause hemorrhages. For example, the victims of Malayan pit viper bite usually develop blood clotting defect due mainly to defibrination and thrombocytopenia. Defibrination is due to the action of the venom thrombin-like enzymes on the fibrinogen. The major thrombin-like enzyme, ancrod, has been used in anticoagulation therapy. Thrombocytopenia is presumably due to the combined actions of the platelet aggregation inducer, aggretin, and the anti-platelet L-amino acid oxidases and phospholipases A. Aggretin, a non-enzymatic protein, is an endothelial integrin  $\alpha_2\beta_1$  agonist which also induces angiogenesis. Other venom constituents of the Malayan pit viper that also contribute to the hemorrhagic actions of the venom include hemorrhagins and platelet aggregation inhibitors. The major hemorrhagin is rhodostoxin, a metalloproteinase which presumably degrades capillary basement membrane. Two platelet aggregation inhibitors, rhodostomin and rhodocetin, have been isolated from the venom. Rhodostomin is an RDG-containing polypeptide that blocks the binding of fibrinogen to the integrin  $\alpha_{IIb}\beta_3$  of platelet whereas Rhodocetin acts as  $\alpha_2\beta_1$  integrin inhibiting disintegrin and may be a valuable tool to manipulate other  $\alpha_2\beta_1$  integrin mediated functions.

## Venomous snakes of Malaysia

Snakebite is a serious medical problem in Malaysia. During the period 1958 to 1980, as many as 55000 cases of snakebites were admitted to the hospitals of Malaysia (Lim and Ibrahim, 1970; Lim, 1982). While the mortality rate is only 0.3 per 100000 population, snake venom poisoning can cause prolonged morbidity or even crippling deformity.

In Malaysia there are at least 18 different species of venomous front fanged land snakes, and more than 22 different species of venomous sea snakes (Tweedie, 1983). These venomous snakes belong to the crotalid (pit viper) family (the genus *Calloselasma* and *Trimeresurus*), elapid family (the genus *Naja*, *Bungarus* and *Ophiophagus*) and sea snake family (the subfamilies *Laticaudinae*, *Hydrophiini* and *Ephalophiini*). Only a few of the Malaysian venomous snakes can be regarded as of medical importance, and these include the pit vipers *Calloselasma rhodostoma* (Malayan pit viper), *Trimeresurus purpurumaculatus*

(shore pit viper), *Trimeresurus wagleri* (Wagler's pit viper) *Trimeresurus sumatranus* (Sumatran pit viper), the elapids *Naja naja sputatrix* (Malayan cobra), *Naja naja kaouthia* (Monocellate cobra), *Ophiophagus Hannah* (king cobra), *Bungarus candidus* (Malayan krait), *Bungarus fasciatus* (banded krait) and the sea snake *Enhydrina schistosa* (beaked sea snake).

Table 1 summarizes the reports on snakebites from monthly statistics of 28 hospitals throughout Malaysia during the six-years period 1965-1971 (Sawai *et al.*, 1972).

**Table 1: Snakebites in West Malaysia (1965-1971)**

Snake Species	Total Cases	Fatal Cases
Malayan pit viper ( <i>Calloselasma rhodostoma</i> )	1136	4
Sea snake	158	5
Asian common cobra ( <i>Naja naja</i> )	112	3
Asian lance-headed viper ( <i>Trimeresurus</i> )	25	0
King cobra ( <i>Ophiophagus hannah</i> )	6	0
Krait ( <i>Bungarus</i> )	1	0
Unidentified	3765	6
Nonpoisonous	184	0

## Composition of snake venom

Dried snake venom contains mainly proteins (70-90%) and small amounts of metals, amino acids, peptides, nucleotides, carbohydrates, lipids and biogenic amines. The protein components include both enzymes and non-enzymatic proteins.

Venoms of many elapid snakes (cobra, krait and sea snakes) produce flaccid paralysis and respiratory failure in animals. These effects are due to the



polypeptide neurotoxins and certain phospholipases A. Elapid venoms also contain various pharmacologically active basic polypeptides. In cobra, the major basic polypeptides are polypeptide cardiotoxins.

The major toxic principles in pit viper venoms are thrombin-like enzymes, hemorrhagic proteases, platelet-aggregation inducers and inhibitors, as well as other enzymes that interfere with the blood coagulation pathway.

Snake venoms consist of many other enzymes, including protease, L-amino acid oxidase, hyaluronidase, phosphodiesterase, alkaline phosphatase and 5-nucleotidase. Most of these enzymes play a role in the digestion of the prey but some also exhibit toxic properties.

## Elapid Venom Poisoning

Elapid venoms (cobra, kraits and sea snakes) generally exhibit neurotoxicity and cardiotoxicity (Lee, 1972; Reid, 1964). The earliest symptom of systemic elapid poisoning is a feeling of drowsiness intoxication, difficulty in opening the eyes (bilateral ptosis). In severe poisoning, respiratory failure sets in rapidly. In cobra, these neurotoxic symptoms are caused by the polypeptide neurotoxins. These are postsynaptic neurotoxins, generally basic polypeptides containing 60-70 amino acid residues with an intravenous  $LD_{50}$  (median lethal dose) of approximately 0.1  $\mu\text{g/g}$  in mouse. Postsynaptic neurotoxins isolated from cobra, krait and sea snake venoms are very similar in their amino acid sequence.

## Toxinology of the Malayan cobra venom

In Malayan cobra (*Naja naja sputatrix*) venom, postsynaptic neurotoxins account for approximately 5% of the venom dry weight. Two major neurotoxins, with 62 and 63 amino acid residues respectively, have been purified (Tan, 1983). The amino acid sequences of the two toxins have been elucidated (Chung *et al*, 1994) as follows:



LECHDQQSSQTPTTGCSGGETNCYKKRWRDHRGYRTERGCGCPSV  
KNGIEINCCTTDRCNN

LECHNQQSSQAPTTKTCSGETNCYKKWWSDRHGTHERGCGCPKV  
KPGVKLNCCTTDRCNN

The neurotoxin genes have also been cloned and expressed (Afifiyan *et al*, 1998)

Cobra venom cardiotoxicity is caused by polypeptide cardiotoxin that impairs the structure and function of various cells, contributing to muscle paralysis and leading to circulatory failure and systolic arrest (Lee, 1972). Polypeptide cardiotoxins account for 60% of the Malayan cobra venom by weight. Three polypeptide cardiotoxins, sputa-cardiotoxin A, B and C have been isolated from the venom (Tan 1982a). They are basic polypeptides with 59-60 amino acid residue with intravenous LD<sub>50</sub>'s of 1.0-1.1 µg/g mouse.

Jeyaseelan *et al* (1998) reported the cDNA cloning of the cardiotoxins and the deduced amino acid sequences of the cardiotoxins. The sequences are homologous to other cobra venom cardiotoxins.

Malayan cobra venom contains substantial quantity of phospholipases A, which account for 15% of the venom dry weight. Three lethal phospholipases A, sputatrix PLA-1, sputatrix PLA-2 and sputatrix PLA-3 have been isolated (Tan, 1982b; Tan and Arunmozhiarasi, 1989). The three enzymes have intravenous LD<sub>50</sub>'s of between 0.28-0.86 µg/g mouse. Sputatrix PLA-3 alone accounts for 10% of the venom protein. It exhibits weak anticoagulant activity and induces contracture of muscle in a chick biventer cervicis nerve-musclepreparation (Geh and Tan, 1988). Sputatrix PLA-2 and PLA-3 exhibit potent anticoagulant activity and are the major anticoagulants of the venom. Following is the sequence of PLA-2:

NLYQFKNMIQCTVPNRSWWHFADYGCYCGRGGSGTPVDDLD  
RCCQVHDNCYGEAEKCWPYFKTYSYECSSQGLTCKGGNACAAAVC  
DCDRLAAICFAGAPYNNNNYNIDLK

Jeyaseelan *et al* (2000) reported the cloning of the phospholipase A genes from Malayan cobra venom. Comparison of the deduced amino acid sequences shows that the signal peptide sequences are conserved, and the three PLA's are highly homologous with slight variations only.

Malayan cobra venom also causes extensive local necrosis. Our investigations indicated that the local necrosis is presumably caused by the synergistic action of cardiotoxin and phospholipase A (Tan and Arunmozhiarasi, 1990)

### **Sea snake venom poisoning and the biochemistry of sea snake venom**

The commonest species of sea snake is the *Enhydrina schistosa* (beaked sea snake). In rat, its venom is neurotoxic acting mainly at the neuromuscular junction. In human, however, the venom is primarily myotoxic (Reid, 1979). The myonecrosis causes generalized muscle movement pains and myoglobinuria. Postsynaptic neurotoxins account for 70% of the venom dry weight. The two major neurotoxins are polypeptides with 60 amino acid residues and the amino acid sequences are homologous to the cobra neurotoxins. The venom contains more than 9 phospholipases A. The major basic phospholipase A which accounts for 7% of the venom dry weight has been isolated and demonstrate to exhibit strong myotoxic activity. Its sequence is similar to the PLA from other venom sources. Two acidic phospholipases A have also been isolated (Tan, 1982c) and they are able to depress muscle excitability due to direct stimulation as well as the response of muscle to nerve stimulation.

### **Venoms of King cobra and Malaysian kraits**

King cobra is one of the world's most dangerous snakes. The snake, however, is generally not aggressive and king cobra bite in man appears to be infrequent. King cobra venom has a much greater enzyme content than other cobra venoms. The major lethal toxins are also polypeptide neurotoxins, and the main systemic effect of king cobra venom poisoning appears to be neurotoxic poisoning. The



major hemorrhagin, the L-amino acid oxidase and two acidic phospholipases A have been isolated (Tan and Saifuddin, 1989a,b, 1990)

There are three species of krait in Malaysia: *Bungarus fasciatus* (banded krait), *Bungarus candidus* (Malayan krait) and *Bungarus flaviceps* (Red-headed krait). The toxinology of the banded krait has been investigated (Lu and Lo, 1981). We have isolated two highly lethal phospholipases A from the Malayan krait (Tan *et al.*, 1989). Little is known about the toxinology of the Red-headed krait.

### Elapid toxins as biomedical tools

Knowledge about snake venom toxins may lead to improvement of treatment of snake venom poisoning and development of effective antivenoms. Besides, the toxins are also valuable molecular probes and pharmacological tools, as well as providing lead compounds for the design of clinically useful drugs.

For example, postsynaptic neurotoxins from cobra and krait venoms play an important role in the understanding of the pathogenesis of auto-immune neuromuscular diseases such as Myasthenia gravis. Codoxin, a neurotoxin isolated from Malayan krait, is a useful tool in the investigation of the molecular basis of Alzheimer's disease. It is also a muscle relaxant. Cobra cardiotoxins, on the other hand, can act as inhibitors of coagulation and platelet aggregation and as research tool in neurobiology because of its ion channel activity.

### Pit Vipers in Malaysia

Pit viper bites usually result in swelling and sometime, local necrosis. The principal characteristic of systemic pit viper poisoning in Malaysia is systemic bleeding, characterized by defibrination and thrombocytopenia (Reid, 1968; Warrell, 1986).

The Malayan pit viper (*Calloselasma rhodostoma*) previously known as *Agkistrodon rhodostoma*, is the commonest cause of snakebite in Peninsular Malaysia. It is a bad tempered snake, quick to strike if disturbed. Fortunately,



only 10% of those bitten developed severe poisoning and death rate is less than 2%.

#### Clinical effects of Malayan pit viper Venom

The intravenous LD<sub>50</sub> for Malayan pit viper venom is 6.1 µg/g mouse, which is considerably less lethal than cobra venom. This partially explains the low mortality rate of Malayan pit viper bites.

Local swelling begins minutes after the bite and may continue to increase from 24 to 72 hours. The swelling, which is due to the extravasations of plasma and red blood cells into tissue, results in discoloration. If large amount of venom has been injected, blisters may form around the bite followed by superficial necrosis.

Systemic poisoning is characterized by systemic bleeding, which may be slight with only a prolonged clotting time or when severe, present as hemorrhagic syndrome with or without shock (Chan 1979). The earliest manifestation of severe systemic poisoning is hemoptysis. Other signs that followed are continued oozing of blood from the wound site, gum bleeding, tooth sockets or ulcers, discoid hemorrhage. In severe systemic poisoning, the blood may remain incoagulable for prolonged period. Reid *et al.* (1963) reported that the systemic bleeding is characterized by defibrination and thrombocytopenia. The major toxins of the Malayan pit viper venoms include thrombin-like enzymes, hemorrhagins, platelet aggregation inducer, platelet aggregation inhibitors, L-amino acid oxidases and phospholipases A (Tan and Ponnudurai, 1996).

#### (i) Thrombin-like enzymes

The venom contains several thrombin-like enzymes. The major form, ancrod, accounts for approximately 7.5% of the venom dry weight (Esnouf and Tunnah, 1967). The enzyme coagulates fibrinogen solution by catalyzing the release of fibrinopeptide A, AP and AY. Clots that formed with ancrod are not cross-linked and are susceptible to rapid lysis by plasmin. When injected into human/animals, it causes continual microcoagulation of fibrinogen but the resulting fibrin is

virtually simultaneously disposed off. Thus, although ancrod is a 'coagulant' *in vitro*, the *in vivo* effect is non-clotting blood because of the very low fibrinogen level. The amino acid sequence (Au *et al.*, 1993) exhibits a high degree of sequence similarity to those of mammalian serine proteinases as well as reptilian fibrinogenases.

The use of ancrod in anticoagulation therapy has been examined in many clinical trials. Ancrod provides optimal therapy for patients suspected of having heparin associated thrombocytopenia and thrombosis (HATT). Depletion of fibrinogen with ancrod results in anticoagulation comparable to therapy with heparin within 12 hours (Cole *et al.*, 1990). Ancrod has also been used in the treatment of acute ischaemic stroke (Sherman *et al.*, 2000)

## (ii) Hemorrhagins

Snake venom hemorrhagins are generally metalloproteinases that probably act by destruction of the collagenous basement membrane and other connective tissue collagens with consequent weakening of the blood vessel wall causing hemorrhagic effect.


The major Malayan pit viper venom hemorrhagin, termed rhodostoxin, has been isolated and its amino acid sequence is homologous to other venom hemorrhagins (Chung *et al.*, 1996). It is a zinc-metalloproteinase with 203 amino acid residues (25 kDa) belonging to class P-I of snake venom hemorrhagin:

NHEIKRHVDIVVVDSRFCTKHSNDLEVIRKVFHEVVNAIIIESYKYMHFGLS  
VNLETWCNGDLINVQEDSYETLKAFGKWRESDLIKHVNHNSNAQFLTDMKF  
IKNIIGKAYLDSICDPERSVGIVQNYHGITLNVAAIMAHEMGHMLGVRHDGE  
YCTCYGSSECIMSSHISDPPSKYFSNCSYYQFWKYIENQNPQCILNKP

Rhodostoxin is a potent hemorrhagin with MHD comparable to the venom hemorrhagins but was not lethal to mice at a dose of 6 µg/g (*i.v.*), indicating that it is not a major lethal factor of the venom as the LD<sub>50</sub> (*i.v.*) of Malayan pit viper venom is around 6 µg/g in mice.

### *Glycobiology of rhodostoxin*

Rhodostoxin is glycosylated with two N-linked glycopeptides attached to residues 91 and 181 (Chung *et al.*, 1996). The glycan chain is a complex type of carbohydrate structure with novel 2,3-linked sialic acid and Galβ(1,3)GlcNAc linkages:



Deglycosylation of rhodostoxin results in an apparent increase in the stability of the hemorrhagin as well as an increased specificity (Tan *et al.*, 1997). It appears that the glycol moieties of rhodostoxin may play a role in the interactions between rhodostoxin and the relevant substrate in the membrane.

Rhodostoxin is also known as kistomin. It inhibited angiogenesis in a dose-dependent manner and induced apoptosis of human endothelial cells by degrading extracellular matrix. (Hsu and Huang, 2004). It may provide a potential strategy in exploring the apoptosis induction of endothelial cells and the drug development in angiogenesis therapy.

### (iii) Platelet aggregation inducer

Platelet aggregation occurs during vascular injury, and coverage of the exposed subendothelium by platelets depends on the recognition of adhesive proteins (fibrinogen, collagen, vWF etc) by specific platelet membrane glycoproteins, many of which are integrins. Among them,  $\alpha_2\beta_1$  (GPIa/IIa) and  $\alpha_{\text{IIb}}\beta_3$  (GPIIb/IIIa) are known to play important roles in mediating adhesion and aggregation of platelets. Snake venom platelet aggregation inducers are known to interact with the integrins.

Malayan pit viper venom exhibits strong platelet aggregation inducing activity which contributes to the thrombocytopenia in the victim. Huang *et al.* (1995) reported the isolation of a potent platelet aggregation inducer, aggrexin, from



the venom. It is a heterodimeric protein (29 kDa) and is devoid of enzymatic activity. It has been suggested that aggrexin is an endothelial integrin  $\alpha_2\beta_1$  agonist (Chung *et al.*, 2001). Study on the interaction of platelet aggregation inducer and collagen would increase our knowledge of platelet-collagen interaction at the molecular level and may provide a new avenue for developing inhibitors to prevent detrimental effects of collagen.

#### (iv) Platelet aggregation inhibitors

Many crotalid snake venoms contain polypeptide platelet aggregation inhibitors known as disintegrins. Generally, the polypeptide disintegrins contain Arg-Gly-Asp (RGD) tripeptide sequence near its carboxyl terminus. The tripeptide RGD plays an essential role in mediating the binding of  $\alpha_{IIb}\beta_3$ .

Teng and Huang (1991) reported the isolation of a disintegrin from Malayan pit viper venom. Termed rhodostomin, it is a 68 amino acid residue polypeptide and inhibits platelet aggregation by blocking the binding of fibrinogen to the integrin  $\alpha_{IIb}\beta_3$  of platelet. The amino acid sequence deduced from the cDNA sequence (Au *et al.*, 1991) indicates that the 68-amino acid sequence of rhodostomin is located at the carboxyl terminus of the precursor protein, which also contains the sequence of rhodostoxin, the major hemorrhagin. It appears that rhodostomin and rhodostoxin share a common gene sequence, suggesting that these proteins may be synergistic in function. Presumably, the metalloprotease degrades capillary basement membrane and the soluble rhodostomin then binds to platelet integrins, inhibiting platelet aggregation, resulting in hemorrhages.

Extensive studies of disintegrins have revealed some potential uses of these peptides in the design of antithrombotic agents, the diagnosis of cardiovascular diseases and as novel tools for the study of cell-adhesion, cell migration, angiogenesis and other integrin-related disorders (Huang, 1998). Yeh *et al.* (2001) reported that rhodostomin inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective  $\alpha_v\beta_3$  blockade of endothelial cells.

Wang *et al* (1999) reported the isolation of a different, RGD-independent platelet aggregation inhibitor from Malayan pit viper venom. Termed rhodocetin, it is a CLP (C-type lectin-like protein) that blocks  $\alpha_2\beta_1$  integrin and is responsible for hampering collagen-induced,  $\alpha_2\beta_1$  integrin-mediated platelet activation, leading to hemorrhages and bleeding disorders of the snakebite victims. Because of its high affinity to  $\alpha_2\beta_1$  integrin, rhodocetin may be a useful agent to study and influence  $\alpha_2\beta_1$  integrin-triggered cell function, like cell adhesion, cell migration or secretion of matrix metalloproteases. Thus, rhodocetin may help not only in treating thrombosis but also in treatments aimed to prevent tumor invasion and metastasis.

#### (v) L-Amino acid oxidases

L-Amino acid oxidase (LAAO) is a flavoprotein which catalyses the transformation of L-amino acids to the corresponding  $\alpha$ -keto acids, with the concomitant release of hydrogen peroxide and ammonia. It is found in the venoms of most venomous snakes and contributes to the yellowish colour of the dry venom powder. LAAO is a major constituent of the Malayan pit viper venom, constituting 30% of the venom dried weight. The enzyme is an acidic glycoprotein with a molecular weight of 132000 (Ponnudurai *et al.*, 1994). The cDNA-deduced amino acid sequence of the enzyme shows 83% identity to LAAOs from Eastern and Western diamondback rattlesnake (Macheroux *et al.*, 2001).

LAAO is thought to contribute to the venom's toxicity, possibly through generation of hydrogen peroxide formed as a result of the reaction it catalyzes. The hydrogen peroxide generated may cause impairment of platelet aggregation. The enzyme was not lethal but exhibited strong edema-inducing activity in rat.

#### (vi) Phospholipase A<sub>2</sub> enzymes

Preliminary studies indicated the presence of four acidic phospholipase A<sub>2</sub> enzymes in the venom (Tan *et al.*, 1986). Tsai *et al.* (2000) reported the isolation



of three acidic PLA<sub>2</sub> and one basic PLA<sub>2</sub>-homolog from the venom. Some of these phospholipases A exhibit anti-platelet activity.

### **(vii) Other venom constituents**

The venom contains at least four different basic proteases with molecular weight of approximately 25000, all of which exhibit moderate edema inducing activity. It also contains more than nine different forms of arginine ester hydrolases, five of which exhibit thrombin-like enzyme activity. Two minor forms of arginine ester hydrolase also exhibit arginine amidase activity (Tan, 1991).

The venom also contains autopharmacological factors that may cause local swelling. The factors may release bradykinin which eventually can lead to shock.

Like all other snake venoms, Malayan pit viper venom contains hyaluronidases which are hydrolytic enzymes that function as 'spreading factor' of the venom.

Malayan pit viper venom contains high level of 5'-nucleotidase activity but moderate to low levels of phosphodiesterase and alkaline phosphomonoesterase activities. Little is known about the toxicological properties of these enzymes.

### **Antivenom therapy of Snake Venom Poisoning**

Antivenom therapy is the only specific treatment of snake venom poisoning that is of proven value. If used correctly, it can reverse most systemic poisoning even when given hours and days after the bite, in the case of pit viper bites. Antivenom, however, is generally ineffective in preventing or lessening local necrotic effects of snake venom poisoning.

The specific, monovalent antivenoms are more effective antidote in snakebite. At present, however, only a few monospecific antivenoms are available for snakebites in Malaysia, and these include anti-Malayan pit viper, anti-Cobra, anti-Sea Snake and anti-King cobra. Our studies suggest that the Polyvalent



Trimeresurus Antivenom (National Institute of Preventive Medicine, ROC) is effective against most Malaysian *Trimeresurus* venoms, and the Polyvalent Elapid Antivenom produced by the same institute is effective against Malaysian cobras and kraits (Tan, 1998).

### **Application of Enzyme-linked Immunosorbent Assay (ELISA) in the diagnosis of the biting species**

The identification of the biting species is important so that the victim can be given the right type of monospecific antivenom. Diagnosis of the biting species can be ascertained by identification of the snake if the patient brings the snake to the hospital. In the absence of the snake, diagnosis can be made by clinical observations. Accurate diagnosis of the biting species, however, can be made by ELISA method.

Double sandwich ELISA has been developed for the diagnosis of bites caused by most Malaysian poisonous snakes (Tan et al., 1992). The ELISA method is very specific and the venom concentration can be readily quantitated.

### **Application of ELISA in snake venom research**

Information on serum kinetics of envenoming is important in the development of a personalized modality of treatment of snakebite, where the amount and frequency of antivenom administration is to be based on the amount of venom injected, and the kinetics of venom distribution in the body. For example, in experimental king cobra venom envenomation, it was found that the level of the major lethal neurotoxin reached peak level 72 hours after the bite (Tan et al, 1994).

### **Prphylactic action of *Mucuna pruriens* against snakebite**

Seed of the Nigerian traditional medicinal plant *Mucuna pruriens* exhibits prophylactic action against snakebite in Nigeria, and it has also been used locally for treatment against snakebites. Preliminary investigation indicated that the

prophylactic action of the seed is due to its ability to elicit antibodies that neutralize certain toxic components of Nigerian snake venoms, including phospholipase A.

The immuoreactivity of mouse anti-*Mucuna pruriens* extract (MPE) IgG against the medically important Malaysian snake venoms was examined using Western blot analysis. Anti-MPE IgG reacted against some proteins from venoms of King cobra, Malayan cobra, Malayan krait and Malayan pit viper, but not that of shore pit viper.

The reactive proteins in most of the venoms appeared to be phospholipases A, indicating that MPE seed extract shared common epitopes with many snake venom phospholipase A. However, several high molecular weight proteins in Malayan pit viper venom were also reactive. The preliminary study suggested that *Mucuna pruriens* may also offer prophylactic protection against Malaysian snake venom poisoning (Marinello *et al.*, 2004).

**For further information, please visit the website: [www.tanngethong.com](http://www.tanngethong.com)**

## REFERENCES

- Afifyan F, Armugam A, Gopalakrishnakone P, Tan NH, Tan CH and Jeyaseelan K (1998) Four new postsynaptic neurotoxins from *Naja naja sputatrix* venom : cDNA cloning, proteinexpression and phylogenetic analysis. *Toxicon* **36**, 1871-76.
- Au LC, Huang YB, Huang TF, Teh GW, Lin HH and Choo KBA (1991) A common precursor for a putative hemorrhagic protein and rhodostomin, a platelet aggregation inhibitor of the venom of *Calloselasma rhodostoma*: Molecular cloning and sequence analysis. *Biochem. Biophys. Res. Commun.* **181**, 585-3.
- Au LC, Lin SB, Chou JS, Teh GW, Chang KJ and Shih CM (1993) Molecular cloning and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from the venom of *Calloselasma rhodostoma*. *Biochem J.* **294**, 387-90.
- Chan KE (1979) Bleeding after Malayan pit viper bites. *Southeast Asian J. Trop. Med. Pub. Hlth.* **10**, 276-9.
- Chung MCM, Tan NH and Arunmozhiarasi A (1994) The amino acid sequence of two postsynaptic neurotoxins isolated from Malayan cobra (*Naja naja sputatrix*) venom. *Toxicon* **32**, 1471-4.
- Chung MCM, Ponnudurai G, Kataoka M, Shimizu S and Tan NH (1996) Structural studies of a major hemorrhagin (rhodostoxin) from the venom of *Calloselasma rhodostoma* (Malayan pit viper). *Arch. Biochem. Biophys.* **325**, 199-208.
- Chung CH, Peng HC and Huang TF (2001) Aggretin, a C-type lectin protein, induces platelet aggregation via integrin  $\alpha_2\beta_1$  and GpIb in a phosphatidylinositol 3-kinase independent pathway. *Biochem. Biophys. Res. Commun.* **285**, 689-95.
- Cole, CW, Fournier, LM and Bormanis, J. (1990) Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod. *Can. J. Surg.* **33**, 207-10.
- Esnouf MP and Tunnah GW (1967) The isolation and properties of the thrombin-like activity from *Ancistrodon rhodostoma* venom. *Br. J. Haemat.* **13**, 581-90.



- Geh SL and Tan NH (1988) Biochemical and pharmacological characteristics of an acidic phospholipase A from the venom of Malayan cobra. *Toxicon* **26**, 22. (Abstract)
- Hsu CC and Huang TF (2004) Effects of kistomin, a snake venom metalloproteinase of *Calloselasma rhodostoma*, on endothelial cells and angiogenesis. Paper presented at the XVII<sup>th</sup> International Congress on Fibrinolysis and Proteolysis. Melbourne, Australia, March 21<sup>st</sup>-25<sup>th</sup>, 2004.
- Huang TF (1998) What have snakes taught us about integrins? *Cellular and Molecular Life Sciences* **54**, 527-40.
- Huang TF, Liu CZ and Yang SH (1995) Aggretin, a novel platelet-aggregation inducer from snake (*Calloselasma rhodostoma*) venom, activates phospholipase C by acting as a glycoprotein 1a/IIa agonist. *Biochem J.* **309**, 1021-7.
- Jeyaseelan K, Armugam A, Lachumanan R, Tan CH and Tan NH (1998) Six isoforms of cardiotoxin in Malayan spitting cobra (*Naja naja sputatrix*) venom: cloning and characterization of cDNAs. *Biochem. Biophys. Acta* **1380**, 209-22.
- Jeyaseelan K, Armugam A, Donghui Ma and Tan NH (2000) Structure and phylogeny of venom group I phospholipase A. *Molecular Biology and Evolution* **17**, 1010-21.
- Lee CY (1972) Chemistry and pharmacology of polypeptide toxins in snake venom. *Annual Review of Pharmacology* **12**, 265-81.
- Lim BL and Ibrahim AB (1970) Bites and stings by venomous animals with special reference to snake bites in West Malaysia. *Med. J. Malaysia* **25**, 128-41.
- Lim TW (1982) Epidemiology of snakebites in Malaysia. *The Snake* **12**, 119-24
- Lu MS and Lo TB (1981) Complete amino acid sequence of two cardiotoxin-like analogues from Bungarus fasciatus snake venom. *Toxicon* **19**, 103-111.
- Macheroux P, Seth O, Bollschweiler C, Schwarz M, Kurfurst M, Au LC and Ghisla S (2001) L-Amino acid oxidase from the Malayan pit viper (*Calloselasma rhodostoma*). Comparative sequence analysis and

characterization of active and inactive forms of the enzyme. Eur J. Biochem. **268**, 1679-86.

Marinello E, Guerranti R, Pagani R, Aguiyi JC, Tan NH and Fung YS (2004) Immunological cross-reactions between snake venoms and anti-*Mucuna pruriens* IgG. Eur. J. Biochem. **271**, s1, p106.

Ponnudurai G, Chung MCM and Tan NH (1994) Purification and properties of the L-amino acid oxidase from Malayan pit viper (*Calloselasma rhodostoma*) venom. Arch. Biochem. Biophys. **313**, 373-8.

Reid HA (1964) Cobra-bites. Br. Med. J. **II**, 540-5.

Reid HA (1968) Symptomology, pathology and treatment of land snake bites in India and Southeast Asia. In: Venomous Animals and Their Venoms. Vol. 1 (Buckely EE, Bucheri W and Deulofeu V Eds). Academic Press, New York, pp 611-42.

Reid HA, Thean PC, Chan KE and Baharom AR (1963) Clinical effects of bites by Malayan viper. Lancet **I**, 617-21.

Reid HA (1979) Symptomatology, pathology and treatment of bites of sea snakes. In: *Handbook of Experimental Pharmacology* (Lee CY Ed.), Vol 52, pp922-55. Springer-Verlag, Berlin.

Sawai Y, Koba K, Okonogi T, Mishima S, Kawamura Y, Chinzei H, Ibrahim AB, Devaraj T, Phong-Aksara S, Puranananda C, Salafranca ES, Sumpaico JS, Tseng CS, Taylor JF, Wu CS and Kuo TP (1972) An epidemiological study of snakebites in the Southeast Asia. Jpn. J. Exp. Med. **42**, 283-307.

Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE. (2000) Intravenous anecrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. **283**, 2395-403.

Tan NH (1982a) Cardiotoxins from the venom of Malayan cobra. Arch. Biochem. Biophys. **218**, 51-8.

Tan NH (1982b) Isolation and preliminary characterization of two toxic phospholipase A from the venom of Malayan cobra. Biochem. Biophys. Acta **719**, 599-605.

Tan NH (1982c) Acidic phospholipase A from the venom of common sea snake



- (*Enhydrina schistosa*). Biochem. Biophys. Acta **717**, 503-8.
- Tan NH (1983) Isolation and characterization of two toxins from the venom of the Malayan cobra (*Naja naja sputatrix*). Toxicon **21**, 201-7.
- Tan NH (1991) The biochemistry of venoms of some venomous snakes of Malaysia – A review. Tropical Biomedicine **8**, 91-103.
- Tan, NH (1998) Protection against Malaysian snake envenomations: comparative potency of some commercial and laboratory-prepared antivenoms. Paper presented at the Symposium on Animal, Plant and Microbial Toxins (Natural Toxins of Malaysia), 28<sup>th</sup> Feb, 1998, Kuala Lumpur, Malaysia. see also [www.tanngethong.com](http://www.tanngethong.com).
- Tan NH and Arunmozhiarisi, A (1989) The anticoagulant activity of Malayan cobra venom and venom phospholipase A. Biochem. Intern. **19**, 803-10.
- Tan NH and Arunmozhiarasi A (1990) In vivo interaction between neurotoxin, cardiotoxin and phospholipase A enzymes isolated from Malayan cobra (*Naja naja sputatrix*) venom. Toxicon **28**, 1193-98.
- Tan NH and Ponnudurai G (1996) The toxinology of *Calloselasma rhodostoma* (Malayan pit viper) venom. Toxin Reviews **15**, 1-17.
- Tan NH and Saifuddin MN (1989a) Isolation and characterization of an unusual form of L-amino acid oxidase from king cobra (*Ophiophagus Hannah*) venom. Biochem. Intern. **19**, 937-44.
- Tan NH and Saifuddin MN (1989b) Purification and characterization of two acidic phospholipase A enzymes from king cobra venom. Intern. J. Biochem. **22**, 481-86.
- Tan NH and Saifuddin MN (1990) Isolation and characterization of a hemorrhagin from the venom of *Ophiophagus Hannah* (king cobra) Toxicon **28**, 385-92.
- Tan NH, Gnanajothy P and Chung MC (1997) Proteolytic specificity of rhodostoxin, the major hemorrhagin of *Calloselasma rhodostoma* (Malayan pit viper) venom. Toxicon **35**, 979-84.
- Tan NH, Kanthimathi MS and Tan CS (1986) Enzymatic activities of *Calloselasma rhodostoma* (Malayan pit viper) venom. Toxicon **24**, 626-30.
- Tan NH, Lim KK and Iskandar MNJ (1994) Kinetics of experimental



- envenomation by *Ophiophagus Hannah* (king cobra) venom. *Toxicon* **32**, p541 (Abstract)
- Tan NH, Poh CH and Tan CS (1989) The lethal and biochemical properties of *Bungarus candidus* (Malayan krait) venom and venom fractions. *Toxicon* **27**, 1065-70
- Tan NH, Yeo KH and Nik Jaafar MI (1992) The use of enzyme-linked immunosorbent assay for the quantitation of *Calloselasma rhodostoma* (Malayan pit viper) venom and venom antibodies. *Toxicon* **30**, 1609-20.
- Teng CM and Huang TF (1991): Snake venom constituents that affect platelet function. *Platelet* **2**: 77-87.
- Tsai IH, Wang YM, Au LC, Ko TP, Chen YH and Chu YF (2000) Phospholipases A from *Calloselasma rhodostoma* venom gland. *Eur. J. Biochem* **267**, 6684-91.
- Tweedie MWF (1983) *The Snakes of Malaya*. Singapore National Printers, Singapore, 165pp.
- Wang R, Kini RM and Chung MCM (1999) Rhodocetin, a novel platelet aggregation inhibitor from the venom of *Calloselasma rhodostoma* (Malayan pit viper): synergistic and noncovalent interaction between its subunits. *Biochemistry* **38**: 7584-93.
- Warrell DA (1986) Tropical snake bite: Clinical studies in Southeast Asia. In: *Natural Toxins* (Harris JB Ed.) Clarendon Press, Oxford, pp. 25-45.
- Yeh CH, Peng HC, Yang RS and Huang TF (2001) Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective  $\alpha_v\beta_3$  blockade of endothelial cells. *Mol. Pharmacol.* **59**, 1333-42.

